Drugs / Fibrogammin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06481995 | Jul 2024 → Jun 2028 expected | coagulation protein disease, hemorrhagic disease, puerperal disorder | University of Zurich | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fibrogammin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481995 ↗ |
| Action | Restore | “The goal is to determine if postpartum blood loss and PPH-related complications can be reduced by replenishing FXIII.” NCT06481995 ↗ |
| Modality | Protein / enzyme biologic | “coagulation factor XIII (FXIII)” NCT06481995 ↗ |
| Route | Intravenous | “Women in the intervention group receive FXIII intravenously in addition to the standard of care treatment for PPH.” NCT06481995 ↗ |